BSE:524661

Stock Analysis Report

Welcure Drugs & Pharmaceuticals

Executive Summary

Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Welcure Drugs & Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

524661

-2.0%

IN Pharmaceuticals

0.5%

IN Market


1 Year Return

-7.4%

524661

-20.5%

IN Pharmaceuticals

0.9%

IN Market

Return vs Industry: 524661 exceeded the Indian Pharmaceuticals industry which returned -20.5% over the past year.

Return vs Market: 524661 underperformed the Indian Market which returned 0.9% over the past year.


Share holder returns

524661IndustryMarket
7 Day0%-2.0%0.5%
30 Day2.0%-7.9%1.0%
90 Dayn/a-7.3%-3.2%
1 Year-7.4%-7.4%-19.7%-20.5%2.8%0.9%
3 Year-83.1%-83.1%-27.8%-29.3%20.3%14.3%
5 Year-81.4%-81.4%-11.5%-14.1%43.1%29.8%

Price Volatility Vs. Market

How volatile is Welcure Drugs & Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Welcure Drugs & Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

173.25x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: 524661 (₹0.5) is trading above our estimate of fair value (₹0.02)

Significantly Undervalued: 524661 is trading above our estimate of fair value.


Price Based on Earnings

PE vs Industry: 524661 is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 524661 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate 524661's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: 524661 is overvalued based on its PB Ratio (20x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Welcure Drugs & Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: 524661 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 524661 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 524661 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 524661's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if 524661's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if 524661's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Welcure Drugs & Pharmaceuticals performed over the past 5 years?

-26.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 524661 is unprofitable, and losses have increased over the past 5 years at a rate of -26.5% per year.

Accelerating Growth: Unable to compare 524661's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 524661 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.4%).


Return on Equity

High ROE: 524661 has a negative Return on Equity (-1.27%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 524661 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 524661 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Welcure Drugs & Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 524661's short term assets (₹298.0K) exceeds its short term liabilities (₹61.0K)

Long Term Liabilities: 524661 has no long term liabilities


Debt to Equity History and Analysis

Debt Level: 524661 is debt free.

Reducing Debt: 524661 has not had any debt for past 5 years.

Debt Coverage: 524661 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 524661 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 524661 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 524661's debt is covered by short term assets.


Next Steps

Dividend

What is Welcure Drugs & Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%0.6%markettop25%2.5%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate 524661's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 524661's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 524661's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524661's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 524661's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of Welcure Drugs & Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Sudhir Chandra (82yo)

7.7yrs

Tenure

₹46,000

Compensation

Mr. Sudhir Chandra, B.Sc., B. Tech (Hons.), Dip. (Ing) has been the Managing Director and Director at Welcure Drugs & Pharmaceuticals Ltd. since February 1, 2012 and August 2006 respectively. Mr. Chandra s ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Sudhir's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Sudhir's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.2yrs

Average Tenure

79yo

Average Age

Experienced Management: 524661's management team is seasoned and experienced (6.2 years average tenure).


Board Age and Tenure

13.2yrs

Average Tenure

Experienced Board: 524661's board of directors are seasoned and experienced ( 13.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Sudhir Chandra (82yo)

    MD & Director

    • Tenure: 7.7yrs
    • Compensation: ₹46.00k
  • Dharam Jain (79yo)

    Founder & Non Executive Director

    • Tenure: 0yrs
    • Compensation: ₹2.12m
  • Murari Bhateja

    CFO & Director

    • Tenure: 14.5yrs
    • Compensation: ₹8.00k
  • Mitashi Bisaria (25yo)

    Company Secretary & Compliance Officer

    • Tenure: 0.3yrs

Board Members

  • Sudhir Chandra (82yo)

    MD & Director

    • Tenure: 7.7yrs
    • Compensation: ₹46.00k
  • Dharam Jain (79yo)

    Founder & Non Executive Director

    • Tenure: 0yrs
    • Compensation: ₹2.12m
  • Murari Bhateja

    CFO & Director

    • Tenure: 14.5yrs
    • Compensation: ₹8.00k
  • Nitin Singhal

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: ₹4.00k

Company Information

Welcure Drugs & Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Welcure Drugs & Pharmaceuticals Limited
  • Ticker: 524661
  • Exchange: BSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹6.755m
  • Shares outstanding: 13.51m
  • Website: https://null

Location

  • Welcure Drugs & Pharmaceuticals Limited
  • B-9 and 10, Laxmi Towers
  • L.S.C., Block C
  • Delhi
  • Delhi
  • 110034
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524661BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2005

Biography

Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India. The company was incorporated in 1996 and is based in Delhi, India. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 12:41
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)